Yesterday, I reported that I sold my position in Merck (MRK) in the Fat Pitch Financials Portfolio. I have some additional performance statistics to provide on this trade. According to Marketocracy, I had a total return of 76.89% on the 5,000 shares of Merck purchased on October 4, 2004. The appreciation in share price alone was
Today I closed out one of the most controversial positions in the Fat Pitch Financials Portfolio, Merck (MRK). The 5,000 shares of Merck held in the Fat Pitch Financials Portfolio at Marketocracy were sold today for $56.00. I just got an email indicating that the 5,000 shares were sold at a net average price of $55.956 including commissions and fees. I
I was just reviewing the new stories queue at Value Investing News when I discovered that Warren Buffett’s Berkshire Hathaway was named ‘Most Respected’ by a Barron’s survey. This doesn’t come as any real surprise to me. It’s really about time that Buffett’s company was recognized as a true corporate leader. Some have speculated that
The numbers are in for the Fat Pitch Financials Portfolio and they are not pretty. My Marketocracy portfolio is down 3.74% this month while the S&P 500 was only down 1.86%. Currently, the Fat Pitch Financials Port is only acheiving an 8.18% annualized rate of return since inception versus 11.79% for the S&P 500. In July, I
I’m a little behind on updating you on the performance of the Fat Pitch Financials Portfolio. Let me quickly update you on how my virtual portfolio did in May. Last month, the Fat Pitch Financials Port returned 1.48%. The S&P 500 returned 3.22% over the same period, so I trailed the index by 1.73%. I’ve
Pfizer (PFE) is a world class pharmaceutical company that develops and manufactures leading prescription medicines. This $181 billion dollar company has many competitive advantages that give it a wide moat, which shields it from the pressures of profit eroding competition.